Pediatric MASLD: Beyond “Fatty Liver” Toward a Cardiometabolic Syndrome That Demands Early Action
A clinical and epidemiologic reading of the 2025 AASLD Practice Statement on MASLD evaluation and management in children Leer este artículo en Español: masld en pediatria del higado graso MASLD (Metabolic dysfunction–Associated Steatotic Liver Disease) is the term that has replaced the former NAFLD (Non-Alcoholic Fatty Liver Disease). It refers to steatotic liver disease associated with metabolic dysfunction—fat accumulation in the liver in individuals with metabolic abnormalities, in whom alcohol intake does not account for the hepatic injury. Not all children with overweight or obesity develop MASLD, although the risk rises substantially. Obesity is the leading risk factor, but it is not synonymous with steatotic liver disease. Estimates suggest that up to 50–60% of children with severe obesity may develop MASLD. To diagnose MASLD, the following are required: evidence of hepatic steatosis (by ultrasound, elastography, MRI, or histology) and at least one feature of metabolic dysf...